Sixteen outpatients who met DSM-III criteria for obsessive-compulsive
disorder completed a 20-week double-blind, crossover trial with fluvoxamine
and placebo. Thirteen (81%) improved with fluvoxamine, while three (19%)
improved with placebo. Fluvoxamine treatment was associated with
significant improvement on measures of obsessive- compulsive symptoms,
anxiety, and depression. Depressed subjects' improvement on
obsessive-compulsive measures correlated with improvement in symptoms of
depression. Nondepressed subjects also showed improvement on measures of
obsessive-compulsive symptoms. In this trial, fluvoxamine was an effective
and safe treatment for obsessive-compulsive disorder.Abstract Teaser